Pliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical ...

Pliant Therapeutics said Sunday that an experimental pill significantly improved lung function in patients with idiopathic pulmonary fibrosis, or IPF, a deadly lung disease with few approved ...

Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis ...

Pliant Therapeutics announces a workforce reduction and cost-saving measures to extend its cash runway for late-stage clinical trials. Pliant Therapeutics, Inc. has announced a significant ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. Pliant Therapeutics ends its Phase 2b IPF trial ...

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...